Literature DB >> 2141781

In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients.

J Maugein1, J L Pellegrin, G Brossard, J Fourche, B Leng, J Reiffers.   

Abstract

This study reports the in vitro activities of vancomycin and teicoplanin against 185 coagulase-negative staphylococcal strains isolated from 80 neutropenic patients who received different antibiotic treatments. All strains were susceptible to vancomycin: MICs for 50 and 90% of strains tested were 2 and 4 mg/liter, respectively. Teicoplanin was less active, and MICs displayed a wider range. For only teicoplanin was there a correlation between resistance and previous treatment. At the 4- and 32-mg/liter breakpoint levels, only 20% of the strains isolated from patients without glycopeptide treatment were intermediate or resistant, whereas 49.2% of the strains from patients who had received vancomycin or teicoplanin or both were intermediate or resistant.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2141781      PMCID: PMC171715          DOI: 10.1128/AAC.34.5.901

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

2.  LY146032: activity and resistance development in vitro.

Authors:  R P Mouton; S L Mulders
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

3.  Teicoplanin-resistant coagulase-negative staphylococcus.

Authors:  A P Wilson; M D O'Hare; D Felmingham; R N Grüneberg
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

4.  Teicoplanin-resistant coagulase-negative staphylococci.

Authors:  V Arioli; R Pallanza
Journal:  Lancet       Date:  1987-01-03       Impact factor: 79.321

5.  The effect of medium and inoculum on the activity of vancomycin and teicoplanin against coagulase-negative staphylococci.

Authors:  D Felmingham; K Solomonides; M D O'Hare; A P Wilson; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

6.  In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.

Authors:  C Watanakunakorn
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

7.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

8.  Comparative in vitro study of teichomycin A2.

Authors:  V Fainstein; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

9.  In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1982-10       Impact factor: 3.267

10.  Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

Authors:  R Pallanza; M Berti; B P Goldstein; E Mapelli; E Randisi; R Scotti; V Arioli
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

View more
  14 in total

1.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 3.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

4.  Molecular epidemiology of Staphylococcus epidermidis in a neonatal intensive care unit over a three-year period.

Authors:  P Villari; C Sarnataro; L Iacuzio
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

5.  In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.

Authors:  M L Sanchez; R P Wenzel; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

6.  Emergence of teicoplanin-resistant coagulase-negative staphylococci.

Authors:  E Cercenado; M E García-Leoni; M D Díaz; C Sánchez-Carrillo; P Catalán; J C De Quirós; E Bouza
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

7.  A multicentre study: Staphylococcus and Enterococcus susceptibility to antibiotics.

Authors:  A Turano; G Ravizzola; L Peroni; T Ceruti; L M Greco; E Pitzus; G Santini; S Cresti; G Satta
Journal:  Eur J Epidemiol       Date:  1994-10       Impact factor: 8.082

Review 8.  Infections due to antibiotic-resistant gram-positive cocci.

Authors:  G M Caputo; M Singer; S White; M R Weitekamp
Journal:  J Gen Intern Med       Date:  1993-11       Impact factor: 5.128

9.  Characterization of coagulase-negative staphylococci causing nosocomial infections in preterm infants.

Authors:  B Neumeister; S Kastner; S Conrad; G Klotz; P Bartmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

10.  Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.

Authors:  P Van der Auwera; M Aoun; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.